Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results

On November 16, 2026 Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, reported financial results for the quarter ended September 30, 2026, and highlighted new clinical findings supporting mipletamig’s potential in frontline acute myeloid leukemia (AML), progress in optimizing treatment tolerability, and continued advancement of its next-generation cancer treatment pipeline.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are entering an exciting period for Aptevo, with growing clinical evidence that reinforces our confidence in mipletamig and meaningful progress across our broader pipeline," said Jeff Lamothe, President and Chief Executive Officer of Aptevo. "We are seeing strong clinical activity in patients with some of the most difficult-to-treat forms of AML, patients advancing to potentially curative stem cell transplantation, and important improvements in tolerability. Each of these findings adds a new dimension to the mipletamig story and strengthens our conviction in its potential to become an important addition to frontline AML treatment. At the same time, we are advancing a new generation of cancer therapies designed to bring the power of our multispecific technology to more patients and more types of cancer. As we approach important clinical and development milestones, we believe Aptevo is increasingly well positioned to translate the strength of our science into meaningful opportunities for patients and long-term value for shareholders."

Business Highlights

Mipletamig delivers a 79% remission rate in one of the hardest-to-treat forms of AML, nearly double a published historical benchmark. In September, Aptevo reported that 14 evaluable TP53-mutated patients treated with mipletamig in combination with venetoclax and azacitidine, including two patients from the previously completed dose expansion trial, 13 (93%) experienced clinical benefit. * Eleven patients achieved CR or CRi (79%), including nine complete remissions.
*Clinical benefit includes complete remission (CR), complete remission with incomplete hematologic recovery (CRi), partial response (PR) and morphologic leukemia-free state (MLFS).

These results are encouraging because patients with TP53-mutated AML have historically had limited treatment success. The 79% CR/CRi rate observed in evaluable patients treated with the mipletamig triplet compares favorably with a published 41% composite remission rate of intent-to-treat, treatment-naïve patients with poor-risk cytogenetics and TP53-mutated AML who received only venetoclax plus azacitidine.**

**Benchmark comparison based on Pollyea DA, et al. Clinical Cancer Research. 2022;28(24):5272-5279. Comparison is to treatment-naïve patients with poor-risk cytogenetics and TP53-mutated AML treated with venetoclax plus azacitidine.

Ten of 47 patients receiving mipletamig combination therapy advances to potentially curative stem cell transplantation. In October, Aptevo reported that ten of 47 evaluable frontline patients treated with mipletamig in combination with venetoclax and azacitidine (VEN+AZA) proceeded to allogeneic stem cell transplantation, a potentially curative treatment option. This includes nine patients from the ongoing Phase 1b RAINIER trial and one patient from the previously completed dose expansion trial. This finding is particularly encouraging in a patient population initially deemed unfit for intensive induction chemotherapy, where advanced age, underlying health conditions and other factors can limit treatment options.
Aptevo significantly reduced infusion-related reactions through refinements to mipletamig’s priming-dose regimen. The adjustment substantially improved tolerability, addressing an important clinical development priority. For patients already facing the challenges of AML treatment, fewer reactions may mean a more manageable treatment experience, while supporting continued advancement toward Phase 2.
Mipletamig approaches a major development milestone as RAINIER nears completion of Phase 1b dose optimization. With study completion targeted by year-end 2026 and regulatory interaction planned for the first half of 2027, Aptevo is moving closer to the next phase of clinical development, bringing mipletamig another step toward its potential role in frontline AML treatment.
Aptevo clears important development hurdles on the path toward human testing of its next generation trispecifics. Progress in manufacturing optimization supports the ability to produce therapeutics that perform more than one immune engaging job in a single molecule – reliably and at the scale needed for further development. This moves Aptevo closer to advancing new treatment candidates for solid tumors, expanding its opportunities beyond AML.
Aptevo expands the potential of its technology to power multiple new cancer treatments. A new patent application covering Nectin-4 × PD-L1 dual-targeting technology could support both immune-based therapies and radiopharmaceuticals. The filing strengthens Aptevo’s intellectual property strategy, creating opportunities to apply its technology across multiple cancer treatment approaches.
Aptevo secures $4.5 million in additional financing to support its next development milestones. In August, existing warrant holders exercised warrants for 254,922 shares at a price of $4.03 per share and purchased 861,708 additional shares (or pre-funded warrants) at the same price in a private placement. Investors also received new warrants covering up to 5,583,150 shares at $4.03 per share, which would provide up to $22.5 million in additional proceeds if exercised. The transaction provides additional capital to advance mipletamig and the Company’s next-generation pipeline, helping fund continued clinical and preclinical progress.
Third Quarter 2026 Financials

Cash position: Cash and cash equivalents totaled $8.3 million as of September 30, 2026, compared with $9.8 million as of June 30, 2026.
Net loss: Net loss for the third quarter of 2026 was $6.5 million, compared with $7.5 million for the third quarter of 2025.
Financing activity: In August 2026, the company completed a warrant inducement and private placement that generated gross proceeds of approximately $4.5 million, or approximately $4.1 million net of $0.4 million in issuance costs.
For additional APVO financial information and complete access to the company’s filings, click here.

(Press release, Aptevo Therapeutics, NOV 16, 2026, View Source [SID1234674824])